JSM 2011 Online Program
The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
Activity Details
|
|
|||
| 70 * | Sun, 7/31/2011, 4:00 PM - 5:50 PM | CC-D236 | |
| Topics in Oncology Studies — Contributed Papers | |||
| Biopharmaceutical Section | |||
| Organizer(s): Ying Lu, Palo Alto VA CSP Coordinating Center/Stanford | |||
| Chair(s): John Boscardin, San Francisco VA/University of California at San Francisco | |||
| 4:05 PM | Escalation with Overdose Control Using Normalized Equivalent Toxicity Score and Patient's Characteristics to Define Personalized Maximum Tolerated Dose in Phase I Clinical Trial — Zhengjia Chen, Emory University ; Mourad Tighiouart, Emory University ; Yuan Liu, Emory University ; Zhibo Wang, Georgia State University ; Taofeek K. Owonikoko, Emory University ; Jeanne Kowalski, Emory University | ||
| 4:20 PM | A Comparison of Longitudinal and Time-to-Endpoint Approaches for Treatment Comparisons in Tumor Growth Studies — Kingshuk Roy Choudhury, University College Cork ; Ian Kasman, Genentech Inc. ; Greg D. Plowman, Genentech Inc. | ||
| 4:35 PM | Exact Group Sequential Designs for Phase I Oncology Trials — Karen Messer, Moores UCSD Cancer Center | ||
| 4:50 PM | Predicting Data Cutoff Dates for Event-Driven Randomized Survival Clinical Trials Before and During Study Conduct — Ying Tian, Amgen Inc. ; Alan Rong, Amgen Inc. ; Alicia Zhang, Amgen Inc. ; Hua Yu, Amgen Inc. | ||
| 5:05 PM | Escalation with Overdose Control using Time to Toxicity Data for Cancer Phase I Clinical Trials — Yuan Liu, Emory University ; Mourad Tighiouart, Emory University ; AndrĂ© Rogatko, Samuel Oschin Comprehensive Cancer Institute | ||
| 5:20 PM | Using Bayesian Proof-of-Concept (POC) Criteria to Design Randomized Phase II Oncology Trials Stratified by Biomarker Status — Kalyanee Appanna, Novartis Oncology ; Valentine Jehl, Novartis Oncology ; Yong Zhang, Novartis Oncology ; Yun Wang, Novartis Oncology ; Amy Racine, Novartis ; Beat Neuenschwander, Novartis Pharma AG ; Emmanuel Zuber, Novartis Oncology | ||
2011 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.